New hope for Hard-to-Treat myeloma: experimental combo enters phase 2
NCT ID NCT07284758
First seen Jan 11, 2026 · Last updated Jun 12, 2026 · Updated 21 times
Summary
This study tests a new drug, cemsidomide, combined with dexamethasone in people with multiple myeloma that has returned or not responded to at least three prior treatments. About 100 adults will receive the drug combo to see if it shrinks tumors and how safe it is. The goal is to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Berenson Cancer Center
RECRUITINGWest Hollywood, California, 90069, United States
Contact
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact
-
START San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Conditions
Explore the condition pages connected to this study.